|1.||Yun, Yeon-Sook: 8 articles (05/2011 - 08/2002)|
|2.||Song, Jie-Young: 6 articles (05/2011 - 05/2004)|
|3.||Ahn, Ji-Yeon: 4 articles (05/2011 - 01/2006)|
|4.||Kim, Mi-Hyoung: 2 articles (05/2011 - 02/2010)|
|5.||Kim, Hyung-Doo: 2 articles (02/2010 - 05/2004)|
|6.||Shim, Ji-Young: 2 articles (02/2010 - 01/2006)|
|7.||Choi, In-Soo: 2 articles (03/2006 - 01/2006)|
|8.||Jeong, Gajin: 2 articles (03/2006 - 01/2006)|
|9.||Lee, Sae-lo-oom: 1 article (05/2011)|
|10.||Lim, Min-Jin: 1 article (05/2011)|
07/01/2007 - "The inhibition of tumor growth and survival elongation was also observed when ginsan was administered 24 h after the CP treatment. "
08/01/2002 - "Taken together, these results suggest that ginsan has an immunopotentiating effects on macrophages and these abilities could be used clinically for the treatment of diseases such as cancer."
01/01/1997 - "Spleen cells became cytotoxic to a wide range of tumor cells without major histocompatibility complex-restriction after 4 or 5 days culture in vitro with ginsan. "
07/01/2007 - "This study evaluates the chemoprotective effect of ginsan on normal mice and the adjuvant effect on tumor bearing mice in combination with cyclophosphamide (CP). "
07/01/2007 - "Chemoprotective and adjuvant effects of immunomodulator ginsan in cyclophosphamide-treated normal and tumor bearing mice."
|2.||Body Weight (Weight, Body)
01/01/1997 - "Indeed, no mice died, which injected with ginsan at 1g/kg body weight intraperitoneally. "
04/01/2006 - "In the present study, the frequency of micronucleated polychromatic erythrocytes (MNPCE) was assessed in the bone marrow of C57BL/6 male mice treated with ginsan [100, 200 or 300 mg/kg body weight (b.w.)] or amifostine (200mg/kg b.w.) 30 min before as well as 15 min after 1.5 Gy of gamma-irradiation. "
01/01/2010 - "The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG), The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS, clinical trials registries and grey literature sources were searched on 24 February 2009 using the following terms: ginseng* OR panax OR ginsan OR "Jen Shen"OR shinseng OR Renshen OR schinseng OR ninjin OR gingilone OR panaxoside* OR ginsenoside* OR protopanaxa* OR protopanaxadiol OR protopanaxatriol OR panaxagin OR ginsenol OR ginsenine and terms for dementia and cognition. "
01/01/2009 - "To elucidate the mechanism of ginsan, expression of inflammation-related genes were screened. "
03/01/2006 - "Protection of Staphylococcus aureus-infected septic mice by suppression of early acute inflammation and enhanced antimicrobial activity by ginsan."
01/01/2009 - "Airway hyperresponsiveness, airway inflammation and lung pathology were assessed in order to evaluate the effect of ginsan against asthma. "
02/01/2010 - "The marked increase of proinflammatory cytokines (IL-1beta, IFN-gamma) and chemokines (MCP-1, MIP-2beta, KC) in CCl(4) treated mice was additionally attenuated by ginsan, thereby preventing leukocyte infiltration and local inflammation. "
01/01/2006 - "The immunomodulator ginsan induces resistance to experimental sepsis by inhibiting Toll-like receptor-mediated inflammatory signals."
03/01/2006 - "The synthesis of inflammatory cytokines, such as tumor necrosis factor-alpha interleukin (IL)-1beta, IL-6, IFN-gamma, IL-12, IL-18 and interferon gamma, was significantly downregulated at the early phase of sepsis in mice that were treated with ginsan before the bacterial challenge. "
|9.||Toll-Like Receptors (Toll-Like Receptor)
|10.||Interleukin-18 (Interleukin 18)